Christiana Kartsonaki

• Survival analysis

  Kartsonaki C., (2016), Diagnostic Histopathology, 22, 263 - 270

• Bile duct basement membrane thickening in primary sclerosing cholangitis.

  Colling R. et al, (2016), Histopathology, 68, 819 - 824

• Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy.

  Findlay JM. et al, (2016), Nat Commun, 7

• γH2AX expression in cytological specimens as a biomarker of response to radiotherapy in solid malignancies.

  Shah K. et al, (2016), Diagn Cytopathol, 44, 141 - 146

• Altered expression of epithelial-to-mesenchymal transition proteins in extraprostatic prostate cancer.

  Verrill C. et al, (2016), Oncotarget, 7, 1107 - 1119

• The Ueno method for substaging pT1 colorectal adenocarcinoma by depth and width measurement: an interobserver study.

  Wang LM. et al, (2015), Colorectal Dis, 17, 674 - 681

• Some matched comparisons of two distributions of survival time

  Kartsonaki C. and Cox DR., (2015), Biometrika, 103, 219 - 224

• Imaging DNA damage allows detection of preneoplasia in the BALB-neuT model of breast cancer.

  Cornelissen B. et al, (2014), J Nucl Med, 55, 2026 - 2031

• Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.

  Cazier JB. et al, (2014), Nat Commun, 5

• Corrigendum: Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.

  Cazier JB. et al, (2014), Nat Commun, 5

• Corrigendum: Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.

  Cazier JB. et al, (2014), Nat Commun, 5

• Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: A study based on 7352 families from the German hereditary breast and ovarian cancer consortium

  Fischer C. et al, (2013), Journal of Medical Genetics, 50, 360 - 367

• Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.

  Fischer C. et al, (2013), J Med Genet, 50, 360 - 367

• Primary and secondary effects: some methodological issues

  Kartsonaki C. et al, (2013), Determined to succeed?

• The fitting of complex parametric models

  Cox DR. and Kartsonaki C., (2012), Biometrika, 99, 741 - 747

• Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers.

  Maia AT. et al, (2012), Breast Cancer Res, 14

• Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.

  Im KM. et al, (2011), Hum Genet, 130, 685 - 699

• Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

  Antoniou AC. et al, (2011), Hum Mol Genet, 20, 3304 - 3321

• Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.

  Ramus SJ. et al, (2011), J Natl Cancer Inst, 103, 105 - 116

• Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.

  Gaudet MM. et al, (2010), PLoS genetics, 6

• Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.

  Gaudet MM. et al, (2010), PLoS Genet, 6

• A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.

  Antoniou AC. et al, (2010), Nat Genet, 42, 885 - 892

Recent Publications

• Survival analysis

  Kartsonaki C., (2016), Diagnostic Histopathology, 22, 263 - 270

• Bile duct basement membrane thickening in primary sclerosing cholangitis.

  Colling R. et al, (2016), Histopathology, 68, 819 - 824

• Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy.

  Findlay JM. et al, (2016), Nat Commun, 7

• γH2AX expression in cytological specimens as a biomarker of response to radiotherapy in solid malignancies.

  Shah K. et al, (2016), Diagn Cytopathol, 44, 141 - 146

• Altered expression of epithelial-to-mesenchymal transition proteins in extraprostatic prostate cancer.

  Verrill C. et al, (2016), Oncotarget, 7, 1107 - 1119